Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scotland starts scrutiny of HCV-infected blood:

This article was originally published in Clinica

Executive Summary

The Scottish government is to hold an inquiry to determine whether haemophiliacs who contracted hepatitis C from contaminated blood products should receive compensation. It recently emerged that the heat treatment used to kill off viruses in blood products in Scotland had not been applied at a sufficiently high temperature and the products may have remained contaminated for up to one year after the UK government had declared them safe in 1986. Unlike haemophiliacs who were infected with HIV, compensation from the UK government has so far been denied to those with hepatitis C.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT079586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel